{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:44:18Z","timestamp":1784583858145,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T00:00:00Z","timestamp":1276041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00774-010-0198-8","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T07:00:19Z","timestamp":1275980419000},"page":"706-712","source":"Crossref","is-referenced-by-count":24,"title":["Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget\u2019s disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Litsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Efstathiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Arsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Moralidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,9]]},"reference":[{"key":"198_CR1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","volume":"347","author":"MP Whyte","year":"2002","unstructured":"Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S (2002) Osteoprotegerin deficiency and juvenile Paget\u2019s disease. N Engl J Med 347:175\u2013184","journal-title":"N Engl J Med"},{"key":"198_CR2","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/hmg\/11.18.2119","volume":"11","author":"T Cundy","year":"2002","unstructured":"Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119\u20132127","journal-title":"Hum Mol Genet"},{"key":"198_CR3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2006-0479","volume":"92","author":"S Simsek","year":"2007","unstructured":"Simsek S, Basoski NM, Bravenboer N, Zhang X, Mumm S, Whyte MP, Netelenbos JC (2007) Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-kappaB, osteoprotegerin, or sequestosome-1 gene defects. J Clin Endocrinol Metab 92:1897\u20131901","journal-title":"J Clin Endocrinol Metab"},{"key":"198_CR4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.berh.2007.11.005","volume":"22","author":"SH Ralston","year":"2008","unstructured":"Ralston SH (2008) Juvenile Paget\u2019s disease, familial expansile osteolysis and other genetic osteolytic disorders. Best Pract Res Clin Rheumatol 22:101\u2013111","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"198_CR5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jbmr.5650090519","volume":"9","author":"F Singer","year":"1994","unstructured":"Singer F, Siris E, Shane E, Dempster D, Lindsay R, Parisien M (1994) Hereditary hyperphosphatasia: 20\u00a0year follow-up and response to disodium etidronate. J Bone Miner Res 9:733\u2013738","journal-title":"J Bone Miner Res"},{"key":"198_CR6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa050893","volume":"353","author":"T Cundy","year":"2005","unstructured":"Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM (2005) Recombinant osteoprotegerin for juvenile Paget\u2019s disease. N Engl J Med 353:918\u2013923","journal-title":"N Engl J Med"},{"key":"198_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1259\/0007-1285-47-553-9","volume":"47","author":"FH Doyle","year":"1974","unstructured":"Doyle FH, Woodhouse NJ, Glen AC, Joplin GF, MacIntyre I (1974) Healing of the bones in juvenile Paget\u2019s disease treated by human calcitonin. Br J Radiol 47:9\u201315","journal-title":"Br J Radiol"},{"key":"198_CR8","first-page":"642","volume":"19","author":"A Spindler","year":"1992","unstructured":"Spindler A, Berman A, Mautalen C, Ubios J, Santini AE (1992) Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature. J Rheumatol 19:642\u2013645","journal-title":"J Rheumatol"},{"key":"198_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bone.2004.03.013","volume":"35","author":"C Tau","year":"2004","unstructured":"Tau C, Mautalen C, Casco C, Alvarez V, Rubinstein M (2004) Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone (NY) 35:210\u2013216","journal-title":"Bone (NY)"},{"key":"198_CR10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1359\/jbmr.040127","volume":"19","author":"T Cundy","year":"2004","unstructured":"Cundy T, Wheadon L, King A (2004) Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 19:703\u2013711","journal-title":"J Bone Miner Res"},{"key":"198_CR11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/JPEM.2000.13.2.217","volume":"13","author":"E Demir","year":"2000","unstructured":"Demir E, Bereket A, Ozkan B, Topcu M (2000) Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J Pediatr Endocrinol Metab 13:217\u2013221","journal-title":"J Pediatr Endocrinol Metab"},{"key":"198_CR12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (NY) 38:617\u2013627","journal-title":"Bone (NY)"},{"key":"198_CR13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1586\/eem.09.35","volume":"4","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Anastasilakis AD, Terpos E (2009) Paget\u2019s disease of bone: emphasis on treatment with zoledronic acid. Expert Rev Endocrinol Metabolism 4:424\u2013434","journal-title":"Expert Rev Endocrinol Metabolism"},{"key":"198_CR14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353:898\u2013908","journal-title":"N Engl J Med"},{"key":"198_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96\u2013110","journal-title":"Hormones (Athens)"},{"key":"198_CR16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1359\/jbmr.2001.16.9.1719","volume":"16","author":"BG Stuckey","year":"2001","unstructured":"Stuckey BG, Lim EM, Kent GN, Ward LC, Gutteridge DH (2001) Bisphosphonate therapy for Paget\u2019s disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission. J Bone Miner Res 16:1719\u20131723","journal-title":"J Bone Miner Res"},{"key":"198_CR17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bone.2006.04.032","volume":"39","author":"HE Whitson","year":"2006","unstructured":"Whitson HE, Lobaugh B, Lyles KW (2006) Severe hypocalcemia following bisphosphonate treatment in a patient with Paget\u2019s disease of bone. Bone (NY) 39:954\u2013958","journal-title":"Bone (NY)"},{"key":"198_CR18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-008-0852-6","volume":"26","author":"A Avramidis","year":"2008","unstructured":"Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget\u2019s disease of bone. J Bone Miner Metab 26:635\u2013641","journal-title":"J Bone Miner Metab"},{"key":"198_CR19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jbmr.5650110206","volume":"11","author":"SA Khan","year":"1996","unstructured":"Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA (1996) Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 11:178\u2013182","journal-title":"J Bone Miner Res"},{"key":"198_CR20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-008-0629-8","volume":"19","author":"JP Devogelaer","year":"2008","unstructured":"Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S (2008) Management of patients with Paget\u2019s disease: a consensus document of the Belgian Bone Club. Osteoporos Int 19:1109\u20131117","journal-title":"Osteoporos Int"},{"key":"198_CR21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","volume":"86","author":"DB Kimmel","year":"2007","unstructured":"Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022\u20131033","journal-title":"J Dent Res"},{"key":"198_CR22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/07315724.2003.10719287","volume":"22","author":"RP Heaney","year":"2003","unstructured":"Heaney RP, Dowell MS, Hale CA, Bendich A (2003) Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22:142\u2013146","journal-title":"J Am Coll Nutr"},{"key":"198_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S8756-3282(98)00163-X","volume":"24","author":"GO Stewart","year":"1999","unstructured":"Stewart GO, Gutteridge DH, Price RI, Ward L, Retallack RW, Prince RL, Stuckey BG, Kent GN, Bhagat CI, Dhaliwal SS (1999) Prevention of appendicular bone loss in Paget\u2019s disease following treatment with intravenous pamidronate disodium. Bone (NY) 24:139\u2013144","journal-title":"Bone (NY)"},{"key":"198_CR24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00520-009-0704-5","volume":"17","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Anastasilakis AD, Terpos E (2009) Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Cancer 17:1329\u20131330","journal-title":"Support Care Cancer"},{"issue":"suppl 2","key":"198_CR25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1359\/jbmr.06s204","volume":"21","author":"S Shankar","year":"2006","unstructured":"Shankar S, Hosking DJ (2006) Biochemical assessment of Paget\u2019s disease of bone. J Bone Miner Res 21(suppl 2):22\u201327","journal-title":"J Bone Miner Res"},{"key":"198_CR26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1055\/s-0029-1233491","volume":"41","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Anastasilakis AD, Efstathiadou Z, Kita M, Litsas I, Avramidis A, Arsos G, Moralidis E, Gerou S, Pavlidou V, Papatheodorou A, Terpos E (2009) The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget\u2019s disease of bone. Horm Metab Res 41:846\u2013850","journal-title":"Horm Metab Res"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-010-0198-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-010-0198-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-010-0198-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:16:40Z","timestamp":1559110600000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-010-0198-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,9]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1007\/s00774-010-0198-8","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,9]]}}}